Esperion Therapeutics (ESPR) Return on Capital Employed (2013 - 2026)
Esperion Therapeutics (ESPR) posted Return on Capital Employed of 46.25% for Q1 2026, down 12.4% on a QoQ basis from 52.8% in Q4 2025, and up 10973.0% year-over-year from N/an in Q1 2025.
Esperion Therapeutics (ESPR) Return on Capital Employed (2013 - 2026) Analysis & Trends
Esperion Therapeutics' Return on Capital Employed history runs 14 years deep, the most recent figure standing at 46.25% for Q1 2026.
- Quarterly Return on Capital Employed rose 10973.0% year-over-year to 46.25% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 46.25% (up 10973.0% YoY) and the FY2025 annual result came in at 57.93%, down 13245.0% from the prior year.
- Return on Capital Employed was 46.25% for Q1 2026 at Esperion Therapeutics, down from 52.8% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 844.13% in Q3 2025 and bottomed at 271.36% in Q4 2023.
- A 5-year average of 11.01% and a median of 66.01% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed sank 17592 bps — and 2025, when it jumped 83430 bps.
- Esperion Therapeutics' Return on Capital Employed stood at 95.44% in 2022, then sank by 184 bps to 271.36% in 2023, then surged by 124 bps to 65.75% in 2024, then dropped by 20 bps to 52.8% in 2025, then decreased by 12 bps to 46.25% in 2026.
- Business Quant data shows ESPR's Return on Capital Employed at 46.25% in Q1 2026, 52.8% in Q4 2025, and 844.13% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | 46.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 46.25% |
| Dec 31, 2025 | 52.80% |
| Sep 30, 2025 | 844.13% |
| Jun 30, 2025 | -96.43% |
| Mar 31, 2025 | -63.47% |
| Dec 31, 2024 | 65.75% |
| Sep 30, 2024 | 9.83% |
| Jun 30, 2024 | 2.64% |
| Mar 31, 2024 | -27.77% |
| Dec 31, 2023 | -271.36% |
| Sep 30, 2023 | -172.52% |
| Jun 30, 2023 | -124.81% |
| Mar 31, 2023 | -119.90% |
| Dec 31, 2022 | -95.44% |
| Sep 30, 2022 | -85.21% |
| Jun 30, 2022 | -85.73% |
| Mar 31, 2022 | -66.01% |
| Dec 31, 2021 | -98.55% |
| Sep 30, 2021 | -152.93% |
| Jun 30, 2021 | -148.04% |